Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ Rl cL(HM
}G{"Mp4
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© ~;$QSO\2h
?Ybq]J\q
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© zdPJ>PNU
6c^?DLy9B
1.Co-stimulators (or co-stimulating molecules) m,kYE9{
g,iW^M
2.NK-kB ~v\
W[
/"`hz6rIv
3.Immunoglobulin superfamily O,
eoO,gB
%pxJ2 7Q
4.antigen-presenting cell (APC) L
/ PAC
|) ~-Wy
5.death domain UZFs]z!,k
qY%|Uo
6.CCR and CXCR TtrO _D
M __S)
7.Lectin (or mitogen) w3
vZ}1|
7&
P70DO
8.Clusters of differentiation, CD) 5V(#nz
F|+B8&-v
9.B7 family -a|b
.p
(FGy"o%TP'
10.Cytotoxic T lymphocyte, CTL) 'z}9BGR!
_VgFuU$h
11.IL-15 and IL-15 receptor (IL-15R) !!ZGNZ_
QPp31o.!5
12.MHC restriction
hFycSu
eV(.\Lj
13.Affinity-chromatography JDa_;bqL
E[ -yfP~[
14.Cyctosprin A, CsA ( -q0!]E
%}N01P|X>
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) _?felxG[
,@p4HN*
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© R86i2',
9k62_]w@6
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 "UY34a
^I
s+ *LVfau
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ U. <c#S
&'/PEOu&}G
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹ÔµÄÌØµã¡£ leSBR,C
ODpAMt"
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© YGyw^$.w
v
?nGAn
ÃâÒßѧרҵ£º F!I9)PSj
SFP?ND+7
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ $LU|
wW
]-heG'y]{
Ïû»¯ÄÚ¿Æ£º y{P~!Yn|
?u{Mz9:?HT
2.Ö×Áö¿¹Ô·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ 1v|0&{lB
V^;lg[:
ѪҺ²¡Ñ§×¨Òµ£º 7<8'7<X
-@'R
YY=
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔÒò£¨Ìõ¼þ£©ÊÇʲô£¿